Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597428 · ClinicalTrials.gov registry record · Phase 3
Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
A Phase 3 study, sponsored by Sucampo Pharma Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
NCT00597428 is a Phase 3 study that has completed, run by Sucampo Pharma Americas. The registered enrollment target is 437 participants.
The verdict
NCT00597428, a Phase 3 study, has completed, sponsored by Sucampo Pharma Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).
Interventions
- DRUG Placebo
- DRUG Lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597428
The ClinicalTrials.gov registry entry for NCT00597428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00597428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597428 about?
NCT00597428 is a clinical study titled "Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone". The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).
What is the current status of trial NCT00597428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00597428?
The interventions under investigation include: Placebo (DRUG), Lubiprostone (DRUG).
Who is sponsoring clinical trial NCT00597428?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.